Trial Profile
Augmentation of HIV-specific helper and CTL [cytotoxic T lymphocytes] responses through therapeutic vaccination in individuals receiving potent suppressive antiretoviral therapies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs HIV vaccine (Primary) ; HIV vaccine vCP1452 (Primary)
- Indications HIV-1 infections
- Focus Pharmacodynamics
- 21 Oct 2005 New trial record.